Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_4
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting133%
unknown267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

NCT04145258
unknownphase_4

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

NCT02483169
unknownphase_4

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

NCT01013532

Clinical Trials (3)

Showing 3 of 3 trials
NCT04145258Phase 3

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

Recruiting
NCT02483169Phase 4

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Unknown
NCT01013532Phase 4

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3